Cowen analyst Doug Schenkel raised his 2019 revenue forecast for Guardant Health by about $14M to $133.8M, which he noted is consistent with management guidance and consensus. While he sees some instances where he believes some expectations for Guardant “have got a bit ahead of themselves,” Schenkel keeps an Outperform rating on the shares and raised his price target to $70 from $40, citing his view that the company has established itself as “the leader in comprehensive liquid biopsy testing for metastatic cancer patients.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.